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==========================

Multiple myeloma (MM) is a clonal B-cell malignancy of terminally differentiated plasma cells. MM is the second most common cancer of blood system. As the aging of the population in recent years, the incidence of this disease increased gradually.\[[@ref1]\] Although the treatment method was improved in the recent 10 years, the outcomes of MM has improved,\[[@ref2][@ref3][@ref4][@ref5]\] patients older than seventy benefits less from these new treatments than younger patients.\[[@ref6]\] At present, many biological and genetic prognostic factors and the International Staging System (ISS) are available to predict outcome; however, these factors are not sufficient to explain the aforementioned age-based difference in the outcome.\[[@ref7][@ref8][@ref9]\] Specific assessment strategies are needed to define the frailty profiles of older patients.\[[@ref10]\] Frailty and comprehensive geriatric assessment (CGA) are being incorporated to guide treatment decisions for cancer patients.\[[@ref11][@ref12]\] However, the value of a geriatric assessment (GA) for MM patients in China has not yet been prospectively evaluated. We assessed the predictive role of a baseline GA in 628 newly diagnosed MM patients to define a frailty score and assess the influence of this score on clinical outcomes and toxicity.

M[ethods]{.smallcaps} {#sec1-2}
=====================

The study was a multicenter retrospective study that enrolled newly diagnosed inpatients from six hospitals from June 2011 to June 2013. Six hundred and twenty-eight patients were enrolled. The patients' demographic features, clinical features, treatments, and outcome data were collected and analyzed \[[Table 1](#T1){ref-type="table"}\]. MM was defined according to the criteria of the International Myeloma Working Group (IMWG).\[[@ref1]\] This study was retrospective, and all patients' data remained anonymous. Therefore, the requirement to obtain informed consent was waived. This study was complied with the *Declaration of Helsinki* and was approved by Beijing Peoples' Hospital Ethics Committees.

###### 

The basic characteristics of the patients

  Characteristics              Number of patients (*n* = 628), *n* (%)   Median (IQR)
  ---------------------------- ----------------------------------------- --------------
  Gender                                                                 
   Female                      276 (43.94)                               --
   Male                        352 (56.05)                               
  Age (years)                                                            
   \<65                        432 (68.79)                               58 (52--66)
   65--75                      159 (25.30)                               
   \>75                        37 (5.89)                                 
  ISS                                                                    
   I                           139 (22.13)                               --
   II                          169 (26.91)                               
   III                         320 (50.95)                               
  ADL                                                                    
   \>4                         206 (32.80)                               4 (3--5)
   ≤4                          422 (67.20)                               
  IADL                                                                   
   \>5                         281 (44.75)                               5 (4--7)
   ≤5                          347 (55.25)                               
  Charlson Comorbidity Index                                             
   ≤1                          476 (75.80)                               0 (0--1)
   ≥2                          152 (24.20)                               
  Therapy                                                                
   Bortezomibbased regimens    287 (45.70)                               --
   Other                       341 (54.30)                               

IQR: Interquartile range; ISS: International Staging System; ADL: Activity of Daily Living; IADL: Instrumental Activity Of Daily Living; --: Not applicable.

The primary objective of this analysis was to identify a simple scoring system based on geriatric parameters to predict overall survival (OS). The secondary objectives included an evaluation of the impact of the frailty scoring system on treatment-related toxicity and progression-free survival (PFS).

The GA consisted of the following three tools: Katz\'s Activities of Daily Living (ADL) index, Lawton\'s Instrumental Activities of Daily Living (IADL) index, and the Charlson Comorbidity Index (CCI). The ADL and the IADL scales were adopted to assess the self-care activities, tasks of household management and independence status. The patients' general conditions, ISS scores, beta-2-microglobulin and albumin levels, and some chromosomal abnormalities were assessed and collected. We also assessed adverse events (AEs) in these patients, and we graded these events according to the National Cancer Institute Common Terminology Criteria (NCI-CTC) for Adverse Events version 3.0.

Statistical analysis {#sec2-1}
--------------------

We used the Kaplan-Meier method to estimate survival and compared between risk groups using log-rank testing. Estimates of the predictive effect of GA for OS were expressed as hazard ratios (*HR*s). A value of *P* ≤ 0.05 was considered to be significant differences. The statistical analysis was performed using Statistical Product and Service Solutions (SPSS) version 22.0 statistical software (SPSS Inc., Chicago, IL, USA).
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=====================

This retrospective study included 628 newly diagnosed MM patients. The median age was 58 years, and the majority of patients (68.79%) were \<65 years \[[Table 1](#T1){ref-type="table"}\]. Among the 628 patients, 50.95% were Stage III, 26.91% were Stage II, and 22.13% were Stage I MM according to the ISS. Four hundred and twenty-two patients (67.2%) had ADL scores ≤4, 347 (55.25%) had IADL scores ≤5, and 152 (24.2%) had CCIs ≥2. Nearly, half of the patients received bortezomib-based treatment.

In this real practice study of MM, a multivariate Cox regression model showed that geriatric components influenced OS. In the frail patients, including those \>75 years old, functional declines indicated by the ADL and IADL scores and the presence of comorbidities were associated with worse OS. Reduced OS was observed for patients aged \>75 years (*HR*: 1.25), for patients with ADL scores ≤4 (*HR*: 1.36) and IADL scores ≤5 (*HR*: 1.31), and for patients with CCI scores ≥2 (*HR*: 1.11) \[[Table 2](#T2){ref-type="table"}\]. The OS did not differ between the fit and the intermediately fit patients. An ISS-adjusted multivariate analysis revealed that the risk of death was higher for patients older than 75 years. The proportions of the frail patients in the ISS I, II, and III risk groups and the OSs of these groups are illustrated \[[Table 3](#T3){ref-type="table"}\]. Grade 3 or higher hematologic AEs were documented in 45 (35.4%) fit, 34 (34%) intermediately fit, and 121 (30.2%) frail patients. The risks of developing a grade ≥3 hematologic AEs were not significantly higher in the intermediately fit (*HR*: 0.99, 95% confidence interval \[*CI*\]: 0.54--1.47, *P* = 1.000) or frail patients (*HR*: 1.16, 95% *CI*: 0.70--1.93, *P* = 0.558) compared with the fit patients. Grade 3 or higher nonhematologic AEs were examined. The risk of developing a grade 3 or higher nonhematologic AE was slightly increased in the intermediately fit group (*HR*: 1.57, 95% *CI*: 0.89--2.77, *P* = 0.121) and significantly increased in the frail patients (*HR*: 1.79, 95% *CI*: 1.11--2.90, *P* = 0.018) compared with the fit patients \[[Table 4](#T4){ref-type="table"}\]. Drug discontinuation for any cause other than progression and death was reported in 25 (19.7%) fit, 22 (22%) intermediately fit, and 140 (34.9%) frail patients. The risk of drug discontinuation was higher in the intermediately fit patients (*HR*: 1.16, 95% *CI*: 0.16--8.26, *P* = 0.882) and significantly higher in the frail patients (*HR*: 3.41, 95% *CI*: 0.78--14.99, *P* \< 0.105) than that in the fit patients. The combination of the ISS with the frailty score identified six groups. The median follow-up time was 13.4 months (8--33 months). The survival curves for these six groups are shown in [Figure 1](#F1){ref-type="fig"}. The frail, ISS II/III patients were considered to be very high-risk patients and exhibited a 3-year OS of 49%. The fit, ISS I patients were deemed to be low-risk patients and exhibited the best prognoses and a 3-year OS of 90%.

###### 

The final Cox regression model\* of the patients

  Variables                      *HR* (95% *CI*)     *P*     Score
  ------------------------------ ------------------- ------- -------
  Age (years)                                                
   \<65                          1                   --      0
   65--75                        1.74 (0.98--3.09)   0.058   1
   \>75                          1.25 (0.44--3.51)   0.677   2
  ADL                                                        
   \>4                           1                   --      0
   ≤4                            1.36 (0.78--2.37)   0.282   1
  IADL                                                       
   \>5                           1                   --      0
   ≤5                            1.31 (0.78--2.20)   0.309   1
  Charlson Comorbidity Index                                 
   ≤1                            1                   --      0
   ≥2                            1.11 (0.61--2.01)   0.736   1
  International Staging System                               
   I                             1                   --      --
   II                            1.26 (0.54--2.94)   0.598   --
   III                           2.19 (1.06--4.53)   0.034   --
  Therapy                                                    
   Other                         1                   --      --
   Contain bortezomib            0.59 (0.35--0.99)   0.046   --

\**HRs* and relative risks are for overall survival in patients with the factors as compared with those without the factors. The model was adjusted for International Staging System and therapy. Harrell's C index=0.75 (95% *CI*: 0.51--0.94), Akaike information criterion=585.90. *HR*: Hazard ratio; *CI*: Confidence interval; ADL: Activity of Daily Living; IADL: Instrumental Activity of Daily Living; ISS: International Staging System; --: Not applicable.

###### 

Additive total score and related rate of overall survival at 3 years

  Additive total score   Patient status         Patients, *n* (%)   Overall survival (%, 95% *CI*)
  ---------------------- ---------------------- ------------------- --------------------------------
  0                      Fit                    127 (20.22)         63 (53.67--72.25)
  1                      Intermediate-fitness   100 (15.92)         63 (53.38--73.90)
  ≥2                     Frail                  401 (63.85)         49 (44.14--54.74)

In univariate Cox model the Harrell's C index = 0.87 (95% *CI*: 0.66--1.01) and the Akaike information criterion = 628.54. In multivariate Cox model the Harrell's C index = 0.72 (95% *CI*: 0.47--0.92) and the Akaike information criterion = 586.36. *CI*: Confidence interval.

###### 

Univariate and multivariate analysis of the impact of the frailty profile for patients on overall survival, progression-free survival, discontinuation rate, and incidence of Grade 3 or higher toxicity

  Variables               Overall survival    Discontinuation   Grade \>3 nonhematologic toxicity   Grade \>3 hematologic toxicity                                                   
  ----------------------- ------------------- ----------------- ----------------------------------- -------------------------------- ------------------- ------- ------------------- -------
  Crude                                                                                                                                                                              
   Fit                    1                   --                1                                   --                               1                   --      1                   --
   Intermediate-fitness   0.97 (0.39--2.40)   0.939             1.16 (0.16--8.26)                   0.882                            1.57 (0.89--2.77)   0.121   0.99 (0.54--1.47)   1.000
   Frail                  1.61 (0.83--3.12)   0.159             3.41 (0.78--14.99)                  0.105                            1.79 (1.11--2.90)   0.018   1.16 (0.70--1.93)   0.558
  Adjusted\*                                                                                                                                                                         
   Fit                    1                   --                1                                   --                               1                   --      1                   --
   Intermediate-fitness   0.80 (0.31--2.06)   0.641             1.10 (0.15--7.91)                   0.923                            1.48 (0.84--2.62)   0.177   1.06 (0.65--1.53)   1.000
   Frail                  1.50 (0.77--2.93)   0.231             3.26 (0.74--14.43)                  0.120                            1.80 (1.11--2.91)   0.018   1.12 (0.67--1.86)   0.671

\*Adjusted for ISS and therapy. *HR*: Hazard ratio; *CI*: Confidence interval; ISS: International Staging System; --: Not applicable.

![OSs of the patients classified into six categories according to recursive partitioning analysis following the combination of two independent prognostic scores, i.e., the frailty score and the ISS score. OSs: Overall survivals; ISS: International Staging System.](CMJ-130-130-g001){#F1}
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The median age observed in the study was similar to the age reported by Dr. Lu *et al*.\[[@ref13]\] This retrospective analysis revealed that the frailty score, which combined age, functional status and comorbidities, was associated with survival and toxicity and could be useful to guide dosage adjustments for the treatment of Chinese MM patients. The frailty profile was relevant to progression, nonhematologic AEs and treatment discontinuation irrespective of the ISS stage and type. The study validated the recent IMWG publication of Dr. Palumbo *et al*.\[[@ref14]\]

In our analysis, the 3-year OS rates were 63% in the fit, 63% in the intermediately fit and 50% in the frail patients. In our results, OS did not significantly differ between groups, primarily because the doses were reduced during the treatment of the fit patients at some centers. The reduced survival of the frail patients was due to reductions in doses and age. A significantly higher cumulative incidence of nonhematologic toxicities and a significantly increased rate of drug discontinuation were observed in the frail patients compared with the fit patients, and the nonhematologic AEs and drug discontinuations might have reduced survival. The findings suggest that dose reductions reduced the occurrence of hematological toxicity but did not affect the toxicity of hematology.

Following the combination of the frailty score with the established ISS, the 3-year OS rates were found to be 49% in the frail, ISS II/III group and 90% in the fit, ISS I group. Maybe people with more advanced stage might have worse physical activity and tolerance with regimen. We hope the combination of the two independent parameters will produce a single index that significantly improved the prognostic value and will consequently serve as an important prediction strategy in the future.

The chronological order of the patient\'s age, the patient\'s performance status, and the doctor\'s clinical judgment are insufficient characteristics to define vulnerable populations. The GA could be used in routine clinical practice and in research to ensure that appropriate elderly patients were selected to facilitate more accurate cross-trial comparisons. Frail patients might benefit from mild methods or even palliative/less supportive treatment.\[[@ref15][@ref16][@ref17]\]

The power of this analysis was great due to the widely representative and fairly homogeneous group of real-world data provided by the six Chinese centers. The GAs were prospectively obtained prior to the initiation of chemotherapy and reflected the patients' baseline health statuses rather than the toxicities induced by the therapies. Older people required special care in terms of treatment decisions, and efficacy and side effects must be carefully balanced.

The study is subject to some limitations. This study was retrospective, the value of the information was not very high, and the ADL and IADL scores from the different centers were not uniform. The treatments differed, and these differences biased the survival time data. Dose adjustments for the frail patients resulted in weak doses, and significant differences were consequently not observed between the fit and frail patients.

In conclusion, this study of real-world MM treatment in China revealed that in the mainland of China, the majority of patients were young, in the later ISS stages, and in poor physical condition. The fit, ISS I patients survived the longest. The specific disease risk factors of a patient need to be established prior to selecting a treatment.
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